Anti-VEGF Use in Ophthalmology

by Jay Duker, Michelle Liang

Overview

The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions.

Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use.

The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents.

Some of the topics covered in Anti-VEGF Use in Ophthalmology:

• Neovascular Age-Related Macular Degeneration
• Proliferative Diabetic Retinopathy
• Retinal Vein Occlusion
• Uveitis
• Neovascular Glaucoma
• Macular Edema
• Retinopathy of Prematurity
• Corneal Disease

Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.

Product Details

ISBN-13:	9781040137239
Publisher:	CRC Press
Publication date:	06/01/2024
Sold by:	Barnes & Noble
Format:	eBook
Pages:	200
File size:	35 MB
Note:	This product may take a few minutes to download.

About the Author

Jay S. Duker, MD, is Professor and Chairman of Ophthalmology at the Tufts Medical Center and Tufts University School of Medicine and Director of the New England Eye Center in Boston, Massachusetts. Dr. Duker graduated from Jefferson Medical College and completed ophthalmology and retina training at the Wills Eye Hospital. His research and clinical interests are focused on the posterior segment ranging from macular degeneration, diabetic retinopathy, and retinal vascular diseases, as well as uveitis and intraocular tumors. He has published more than 280 journal articles and has been lead editor on six books and dozens of book chapters. Dr. Duker is the co-editor of the International Journal of Retina and Vitreous.

Michelle C. Liang, MD, is Assistant Professor of Ophthalmology at the Tufts University School of Medicine and a vitreoretinal specialist at the New England Eye Center in Boston, Massachusetts. She graduated with honors from Johns Hopkins University with a degree in Biology and earned her medical degree from the University at Buffalo School of Medicine and Biomedical Sciences. She performed her residency in ophthalmology at the New England Eye Center at Tufts Medical Center and went on to complete a vitreoretinal surgery fellowship at the New England Eye Center and Ophthalmic Consultants of Boston.
Dr. Liang has authored numerous scientific papers and book chapters and has presented at several national meetings. She treats all conditions of the retina and vitreous, including macular degeneration, vitreomacular disorders, diabetic retinopathy, retinal vascular disorders, retinal detachment, and cataract complications. Her research interests include retinal imaging and new therapies for macular degeneration, diabetic macular edema, and other diseases. Dr. Liang is a board-certified member of the American Board of Ophthalmology and a member of the American Academy of Ophthalmology and American Society of Retinal Specialists.

Table of Contents

Dedication About the Editors Contributing AuthorsIntroduction Section I Overview of Anti-Vascular Endothelial Growth Factor Agents Chapter 1 Vascular Endothelial Growth Factor: Background and HistoryAnthony Joseph, MD and Ehsan Rahimy, MD Chapter 2 Development of Anti-Vascular Endothelial Growth Factor AgentsMaya H. Maloney, MD and Sophie J. Bakri, MD Chapter 3 Available Anti-Vascular Endothelial Growth Factor AgentsAngeline Mariani Derham, MD and David M. Brown, MD, FACS Chapter 4 Agents Under Study Ehsan Rahimy, MD; Elham Rahimy, BS; and Anthony Joseph, MD Chapter 5 Intravitreal DeliveryNora Muakkassa, MD; Kendra Klein, MD; and Elias Reichel, MD Chapter 6 Sustained Delivery Options Under StudyMichael N. Cohen, MD; Chirag P. Shah, MD, MPH; and Jeffrey S. Heier, MD Section II Use of Anti-Vascular Endothelial Growth Factor Agents in Clinical Practice Chapter 7 Neovascular Age-Related Macular DegenerationMichael D. Lewen, MD and Andre J. Witkin, MD Chapter 8 Choroidal Neovascularization, Not Age-Related Macular DegenerationDarin R. Goldman, MD Chapter 9 Diabetic Macular EdemaEmily D. Cole, BS; Eduardo A. Novais MD; and Nadia K. Waheed, MD, MPH Chapter 10 Proliferative Diabetic RetinopathySabin Dang, MD and Chirag P. Shah, MD, MPH Chapter 11 Retinal Vein OcclusionShilpa Desai, MD and Caroline R. Baumal, MD Chapter 12 UveitisLana M. Rifkin, MD Chapter 13 Retinopathy of PrematurityNikisha A. Kothari, MD and Audina M. Berrocal, MD Chapter 14 Miscellaneous Retinal and Choroidal DiseasesMichael D. Tibbetts, MD Chapter 15 Neovascular GlaucomaManik Goel, MD and Joel S. Schuman, MD, FACS Chapter 16 Glaucoma SurgeryJessica J. Moon, MD and Cynthia Mattox, MD Chapter 17 Anterior Segment DiseasesAlessandro Abbouda, MD; Bijan Khaksari, BA; and Pedram Hamrah, MD, FRCSFinancial Disclosures Index

Editorial Reviews

Reviewer: Diana V Do, MD (Stanford University School of Medicine)
Description: Anti-VEGF therapy has been widely used in treating diseases characterized by neovascularization. This book covers various aspects of anti-VEGF therapy, including recent developments, future course of VEGF pathway inhibition, and the clinical impact of VEGF inhibition in various ocular pathologies.
Purpose: The purpose is to provide a useful reference to professionals in the field of ophthalmology. Considering the significance of VEGF in this field, this book provides a good review that will help clinicians make sound clinical decisions.
Audience: This book is intended for professionals at all levels of expertise in the field of ophthalmology. Jay Duker, Michelle Liang, and the rest of the authors are accomplished individuals in this field.
Features: To be able to manage patients with ocular diseases involving neovascularization, it is important to understand the role of anti-VEGF, and this book provides a well-rounded review. The relevance of anti-VEGF in a clinical setting and clinical correlation makes for interesting reading. The mechanism of action, available options, and routes of administration are covered appropriately. The unique role of anti-VEGF in all major neovascular diseases is explained well.
Assessment: The concise nature of this book provides a good review of one of the most important agents in ophthalmology. This is a great reference for ophthalmology enthusiasts and experts alike.

Doody's Review Service